Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

Description: Benign Prostatic Hyperplasia - Pipeline Review, H1 2016

Summary


The report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia
- The report reviews pipeline therapeutics for Benign Prostatic Hyperplasia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Benign Prostatic Hyperplasia therapeutics and enlists all their major and minor projects
- The report assesses Benign Prostatic Hyperplasia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Benign Prostatic Hyperplasia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Contents:

List of Tables
List of Figures
Introduction
Report Coverage
Benign Prostatic Hyperplasia Overview
Therapeutics Development
Pipeline Products for Benign Prostatic Hyperplasia - Overview
Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis
Benign Prostatic Hyperplasia - Therapeutics under Development by Companies
Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes
Benign Prostatic Hyperplasia - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Benign Prostatic Hyperplasia - Products under Development by Companies
Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes
Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
AndroScience Corporation
Aphios Corporation
Ausio Pharmaceuticals, LLC
BCWorld Pharm Co. Ltd.
Chong Kun Dang Pharmaceutical Corp.
Dongkook Pharmaceutical Co., Ltd.
Euroscreen S.A.
Hanmi Pharmaceuticals, Co. Ltd.
Jeil Pharmaceutical Co., Ltd.
Kaken Pharmaceutical Co., Ltd.
Benign Prostatic Hyperplasia - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(dutasteride + tadalafil) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
(tadalafil + tamsulosin hydrochloride) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASC-JM.X2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AUS-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BCWPE-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BL-214 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CKD-902 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ESN-364 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fadanafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fexapotide triflutate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HCP-1303 - Drug Profile
Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile

Product Description
Mechanism of Action
R&D Progress

SOM-2391 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

SOM-2393 - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Sperol - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress

tadalafil - Drug Profile
Product Description
Mechanism of Action
R&D Progress

talaporfin sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress

tamsulosin hydrochloride CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints

Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia

Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH

Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study

Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207

Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug

May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016

Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Investigation by Universities/Institutes, H1 2016
Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H1 2016
Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H1 2016
Benign Prostatic Hyperplasia - Pipeline byAusio Pharmaceuticals, LLC, H1 2016
Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Eurascreen S.A., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Monosol Rx, LLC, H1 2016
Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H1 2016
Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H1 2016
Benign Prostatic Hyperplasia - Pipeline by SOM Innovation Biotech SL, H1 2016
Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H1 2016
Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Benign Prostatic Hyperplasia Therapeutics - Recent Pipeline Updates, H1 2016
Benign Prostatic Hyperplasia - Dormant Projects, H1 2016
Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H1 2016
Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H1 2016
Benign Prostatic Hyperplasia - Dormant Projects (Contd..3), H1 2016
Benign Prostatic Hyperplasia - Discontinued Products, H1 2016
List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H1 2016
Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Assessment by Combination Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3753850/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Benign Prostatic Hyperplasia - Pipeline Review, H1 2016
Web Address: http://www.researchandmarkets.com/reports/3753850/
Office Code: SCPLAQ32

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:
Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World